Polaris Venture Management Co. V, L.L.C. - Q2 2021 holdings

$62.4 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 12.5% .

 Value Shares↓ Weighting
FATE  Fate Therapeutics, Inc.$49,461,000
+5.3%
569,8890.0%79.24%
+30.1%
LYRA  Lyra Therapeutics, Inc.$8,840,000
-30.7%
1,100,8520.0%14.16%
-14.4%
XFOR  x4 Pharmaceuticals Inc.$2,025,000
-24.5%
311,4920.0%3.24%
-6.7%
LIFE  Atyr Pharma Inc.$637,000
+9.6%
130,5720.0%1.02%
+35.6%
DARE SellDare Bioscience, Inc.$617,000
+12.0%
326,240
-0.0%
0.99%
+38.5%
GNCA  Genocea Biosciences, Inc.$462,000
-13.6%
197,3450.0%0.74%
+6.6%
PULM  Pulmatrix, Inc.$374,000
-21.8%
359,4410.0%0.60%
-3.4%
SELB ExitSelecta Biosciences, Inc.$0-2,773,479
-100.0%
-16.27%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings